|  |
| --- |
| **Tabla 1. Cali, Colombia. Tasa de incidencia media anual de cáncer infantil por millón personas-año según categorías diagnosticas en niños, durante 1977-2011** |
| **Categorías diagnosticas** | **1977-1981** | **1982-1991** | **1992-1996** | **1997-2001** | **2002-2006** | **2007-2011** |
| ***n*** | **TEE** | ***n*** | **TEE** | ***n*** | **TEE** | ***n*** | **TEE** | ***n*** | **TEE** | ***n*** | **TEE** |
| **I Leucemia** | **55** | **53,0** | **85** | **40,9** | **70** | **62,7** | **94** | **75,8** | **71** | **52,6** | **72** | **52,5** |
|  I(a) Leucemia aguda linfoide  | 41 | 40,0 | 57 | 27,4 | 56 | 50,4 | 78 | 63,6 | 56 | 42,6 | 56 | 40,6 |
|  I(b) Leucemia aguda no linfoide | 3 | 2,5 | 16 | 7,7 | 11 | 9,6 | 13 | 9,7 | 10 | 6,7 | 10 | 7,9 |
|  I(c) Leucemia mieloide crónica | 2 | 1,9 | 1 | 0,4 | 1 | 0,7 | 1 | 0,8 | 1 | 0,6 | 4 | 2,5 |
|  I(d) Otras leucemias especificadas | 0 | - | 2 | 0,8 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 1 | 0,9 |
|  I(e) Leucemias no especificadas | 9 | 8,6 | 9 | 4,6 | 2 | 1,9 | 2 | 1,8 | 4 | 2,7 | 1 | 0,6 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **II Linfomas y neoplasias reticuloendoteliales** | **29** | **26,8** | **72** | **33,5** | **28** | **23,4** | **38** | **30,0** | **42** | **29,8** | **45** | **27,2** |
|  II(a) Linfoma Hodgkin | 9 | 7,8 | 29 | 13,2 | 11 | 8,5 | 9 | 7,2 | 13 | 8,9 | 13 | 7,5 |
|  II(b) Linfoma no Hodgkin | 12 | 11,9 | 16 | 7,4 | 4 | 3,3 | 13 | 9,9 | 11 | 7,4 | 12 | 7,1 |
|  II(c) Linfoma de Burkitt | 4 | 3,7 | 16 | 7,7 | 7 | 6,2 | 16 | 12,9 | 15 | 10,8 | 17 | 10,5 |
|  II(d) Neoplasias linforeticulares misceláneas | 0 | - | 4 | 1,8 | 1 | 1,0 | 0 | 0,0 | 0 | 0,0 | 2 | 1,5 |
|  II(e) Linfoma no especificado |  |  | 7 | 3,4 | 5 | 4,4 | 0 | 0,0 | 3 | 2,7 | 1 | 0,6 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **III Neoplasias del SNC e intracraneales** | **19** | **16,8** | **38** | **17,1** | **22** | **18,7** | **40** | **32,2** | **28** | **20,0** | **39** | **28,0** |
|  III(a) Ependimoma | 0 | - | 3 | 1,4 | 2 | 1,6 | 5 | 4,2 | 3 | 2,1 | 4 | 3,0 |
|  III(b) Astrocitoma | 8 | 7,0 | 9 | 4,1 | 8 | 6,9 | 16 | 12,8 | 8 | 5,6 | 15 | 11,1 |
|  III(c) Tumores neuroectodermicos primitivos | 2 | 1,7 | 11 | 4,8 | 6 | 5,0 | 5 | 3,8 | 6 | 4,6 | 10 | 7,6 |
|  III(d) Otros gliomas | 1 | 0,9 | 1 | 0,4 | 2 | 1,7 | 7 | 5,7 | 6 | 4,0 | 5 | 3,2 |
|  III(e) Neoplasias intracraneales e intraespinales | 8 | 7,3 | 0 | - | 1 | 0,7 | 0 | 0,0 | 1 | 0,6 | 3 | 1,9 |
|  III(f) Neoplasias intracraneales e intraespinales NOS | 0 | - | 14 | 6,3 | 3 | 2,8 | 7 | 5,7 | 4 | 3,1 | 2 | 1,3 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **IV Tumores del sistema nervioso simpático** | 5 | 5,7 | 7 | 3,6 | 5 | 5,0 | 6 | 5,6 | 5 | 4,0 | 6 | 4,7 |
|  IV(a) Neuroblastoma y ganglioneuroblastoma | 5 | 5,7 | 7 | 3,6 | 5 | 5,0 | 6 | 5,6 | 5 | 4,0 | 6 | 4,7 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **V Retinoblastoma** | **4** | **4,5** | **8** | **4,3** | **6** | **5,5** | **13** | **12,4** | **5** | **4,5** | **7** | **6,1** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **VI Tumores renales** | **4** | **4,0** | **19** | **9,6** | **2** | **1,8** | **8** | **7,0** | **8** | **7,1** | **8** | **6,8** |
|  VI(a) Tumor de Wilms, rabdoide y sarcoma de células claras | 4 | 4,0 | 18 | 9,2 | 2 | 1,8 | 8 | 7,0 | 8 | 7,1 | 8 | 6,8 |
|  VI(c) Otros tumores malignos renales no especificados | 0 | - | 1 | 0,4 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **VII Tumores hepáticos** | **1** | **0,8** | **6** | **3,0** | **1** | **0,8** | **0** | **0,0** | **3** | **2,5** | **2** | **1,5** |
|  VII(a) Hepatoblastoma | 0 | - | 4 | 2,0 | 1 | 0,8 | 0 | 0,0 | 2 | 1,8 | 2 | 1,5 |
|  VII(b) Carcinoma hepático | 1 | 0,8 | 1 | 0,5 | 0 | 0,0 | 0 | 0,0 | 1 | 0,7 | 0 | 0,0 |
|  VII(c) Tumor hepático no especificado | 0 | - | 1 | 0,4 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **VIII Tumores malignos del hueso** | **4** | **3,1** | **14** | **6,0** | **5** | **3,6** | **8** | **5,5** | **16** | **10,3** | **8** | **4,5** |
|  VIII(a) Osteosarcomas | 3 | 2,4 | 9 | 3,8 | 3 | 2,2 | 5 | 3,6 | 11 | 6,9 | 4 | 2,2 |
|  VIII(b) Condrosarcomas | 0 | - | 0 | - | 1 | 0,7 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
|  VIII(c) Sarcoma de Ewing | 1 | 0,8 | 5 | 2,1 | 1 | 0,7 | 3 | 2,0 | 1 | 0,7 | 3 | 1,7 |
|  VIII(d) Otros tumores malignos específicos de hueso  | 0 | - | 0 | - | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 1 | 0,6 |
|  VIII(e) Otro tumores óseos no especificados | 0 | - | 0 | - | 0 | 0,0 | 0 | 0,0 | 4 | 2,7 | 0 | 0,0 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **IX Sarcoma - tejidos blandos** | **6** | **6,2** | **11** | **5,2** | **12** | **10,0** | **12** | **9,4** | **10** | **6,4** | **15** | **10,7** |
|  IX(a) Rabdomiosarcoma y sarcoma embrionario | 2 | 2,3 | 7 | 3,5 | 9 | 7,8 | 5 | 4,1 | 2 | 1,2 | 7 | 5,4 |
|  IX(b) Fibrosarcoma, neurofibrosarcoma y otras neoplasias fibromatosis | 1 | 1,1 | 0 | - | 1 | 0,8 | 1 | 0,7 | 1 | 0,7 | 1 | 0,6 |
|  IX(d) Otros sarcomas de tejido blandos especificados | 0 | - | 2 | 0,8 | 0 | 0,0 | 5 | 3,7 | 5 | 3,2 | 4 | 2,4 |
|  IX(e) Otros sarcomas de tejidos blandos no especificados | 0 | - | 2 | 0,9 | 2 | 1,4 | 1 | 1,0 | 2 | 1,3 | 3 | 2,3 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **X Tumores de células germinales, trofoblásticos** | **0** | **-** | **10** | **4,8** | **5** | **4,6** | **4** | **3,8** | **4** | **3,6** | **7** | **4,8** |
|  X(a) Tumores de células germinales intracraneales | 0 | - | 2 | 0,8 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 3 | 1,7 |
|  X(b) Tumores de células germinales extracraneales | 0 | - | 0 | - | 0 | 0,0 | 2 | 1,9 | 0 | 0,0 | 1 | 0,8 |
|  X(c) Tumores malignos gonadales de células germinales | 0 | - | 7 | 3,6 | 5 | 4,6 | 2 | 1,9 | 4 | 3,6 | 2 | 1,3 |
|  X(d) Carcinoma gonadal | 0 | - | 0 | - | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
|  X(e) Tumores malignos gonadales y otros no especificados | 0 | - | 1 | 0,4 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 1 | 0,9 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **XI Carcinomas y otras neoplasias epiteliales** | **7** | **6,1** | **8** | **3,5** | **8** | **6,8** | **4** | **2,6** | **8** | **5,4** | **7** | **4,4** |
|  XI(a) Carcinoma adrenocortical | 0 | - | **1** | **0,5** | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
|  XI(b) Carcinoma de tiroides | 0 | - | **0** | **-** | 1 | 0,7 | 0 | 0,0 | 1 | 0,6 | 2 | 1,1 |
|  XI(c) Carcinoma nasofaríngeo | 0 | - | **1** | **0,4** | 0 | 0,0 | 2 | 1,3 | 0 | 0,0 | 1 | 0,6 |
|  XI(d) Melanoma maligno | 2 | 1,7 | **2** | **0,8** | 2 | 1,9 | 0 | 0,0 | 1 | 0,9 | 3 | 2,2 |
|  XI(f) Otros carcinomas y los no especificados | 5 | 4,4 | **4** | **1,3** | 5 | 4,1 | 2 | 1,3 | 6 | 3,9 | 1 | 0,6 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **XII Otros tumores malignos y los no especificados** | **3** | **3,0** | **3** | **1,5** | **1** | **0,8** | **1** | **0,9** | **3** | **2,2** | **6** | **4,4** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Todos** | 137 | 130,1 | 281 | 133,1 | 165 | 143,7 | 228 | 185,3 | 203 | 148,4 | 222 | 155,6 |
| Tasa media anual por millón niños-añoTEE: Tasa estandarizada por edad por millón (método directo, Población Estándar Mundial) |

|  |
| --- |
| **Tabla 2. Cali, Colombia. Tasa de incidencia media anual de cáncer infantil por millón según categorías diagnosticas en niñas, durante 1977-2011** |
| **Categorías diagnósticas** | 1977-1981 | 1982-1991 | 1992-1996 | 1997-2001 | 2002-2006 | 2007-2011 |
| *n* | TEE | *n* | TEE | *n* | TEE | *n* | TEE | *n* | TEE | *n* | TEE |
| **I Leucemia** | **38** | **35,1** | **91** | **44,7** | **69** | **61,7** | **64** | **51,9** | **79** | **64,2** | **75** | **55,7** |
|  I(a) Leucemia aguda linfoide  | 25 | 23,2 | 73 | 35,8 | 51 | 45,4 | 55 | 44,7 | 63 | 51,1 | 61 | 45,4 |
|  I(b) Leucemia aguda no linfoide | 0 | - | 10 | 5,0 | 12 | 10,6 | 7 | 5,8 | 12 | 9,9 | 9 | 6,7 |
|  I(c) Leucemia mieloide crónica | 8 | 7,2 | 2 | 0,8 | 0 | 0,0 | 0 | 0,0 | 1 | 0,6 | 2 | 1,5 |
|  I(d) Otras leucemias especificadas | 1 | 1,1 | 0 | - | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 1 | 0,9 |
|  I(e) Leucemias no especificadas | 4 | 3,5 | 6 | 3,2 | 6 | 5,7 | 2 | 1,3 | 3 | 2,6 | 2 | 1,2 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **II Linfomas y neoplasias reticuloendoteliales** | **14** | **13,2** | **27** | **12,9** | **18** | **15,9** | **12** | **10,1** | **22** | **15,2** | **16** | **11,2** |
|  II(a) Linfoma Hodgkin | 5 | 4,3 | 5 | 2,2 | 6 | 4,6 | 3 | 2,5 | 2 | 1,2 | 5 | 3,2 |
|  II(b) Linfoma no Hodgkin | 6 | 5,5 | 8 | 3,6 | 4 | 3,5 | 1 | 0,8 | 12 | 7,9 | 6 | 4,3 |
|  II(c) Linfoma de Burkitt | 0 | - | 9 | 4,6 | 4 | 4,0 | 5 | 4,4 | 6 | 4,7 | 4 | 3,2 |
|  II(d) Neoplasias linforeticulares misceláneas | 0 | - | 1 | 0,6 | 1 | 1,0 | 0 | 0,0 | 1 | 0,7 | 1 | 0,6 |
|  II(e) Linfoma no especificado | 3 | 3,4 | 4 | 2,0 | 3 | 2,8 | 3 | 2,4 | 1 | 0,6 | 0 | 0,0 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **III Neoplasias del SNC e intracraneales** | **18** | **16,9** | **34** | **16,6** | **25** | **22,1** | **31** | **24,0** | **44** | **32,4** | **33** | **23,1** |
|  III(a) Ependimoma | 2 | 2,0 | 2 | 1,1 | 3 | 2,8 | 1 | 0,8 | 5 | 4,0 | 5 | 3,1 |
|  III(b) Astrocitoma | 5 | 4,4 | 11 | 5,3 | 8 | 7,3 | 17 | 13,6 | 22 | 15,5 | 9 | 6,4 |
|  III(c) Tumores neuroectodermicos primitivos | 4 | 3,8 | 3 | 1,4 | 4 | 3,2 | 2 | 1,6 | 9 | 6,9 | 10 | 7,8 |
|  III(d) Otros gliomas | 0 | - | 4 | 1,9 | 5 | 4,4 | 2 | 1,4 | 1 | 0,7 | 5 | 3,2 |
|  III(e) Neoplasias intracraneales e intraespinales | 7 | 6,7 | 0 | - | 2 | 1,4 | 2 | 1,3 | 3 | 2,0 | 1 | 0,6 |
|  III(f) Neoplasias intracraneales e intraespinales no especificadas | 0 | - | 14 | 6,8 | 3 | 3,0 | 7 | 5,3 | 4 | 3,2 | 3 | 2,1 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **IV Tumores del sistema nervioso simpático** | **6** | **6,3** | **9** | **4,7** | **4** | **3,5** | **5** | **4,5** | **3** | **2,3** | **7** | **6,1** |
|  IV(a) Neuroblastoma y ganglioneuroblastoma | 5 | 5,2 | 9 | 4,7 | 4 | 3,5 | 5 | 4,5 | 1 | 0,9 | 7 | 6,1 |
|  IV(b) Otros tumores del sistema nervioso simpático | 1 | 1,1 | 0 | - | 0 | 0,0 | 0 | 0,0 | 2 | 1,3 | 0 | 0,0 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **V Retinoblastoma** | **8** | **8,9** | **12** | **6,5** | **5** | **5,2** | **8** | **7,9** | **5** | **4,7** | **7** | **6,1** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **VI Tumores renales** | **7** | **8,0** | **12** | **6,5** | **8** | **7,0** | **12** | **11,0** | **9** | **8,0** | **9** | **6,9** |
|  VI(a) Tumor de Wilms, rabdoide y sarcoma de células claras | 7 | 8,0 | 11 | 6,1 | 8 | 7,0 | 11 | 10,1 | 9 | 8,0 | 8 | 6,3 |
|  VI(c) Otros tumores malignos renales no especificados | 0 | - | 1 | 0,5 | 0 | 0,0 | 1 | 1,0 | 0 | 0,0 | 1 | 0,6 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **VII Tumores hepáticos** | **1** | **1,1** | **1** | **0,6** | **4** | **4,2** | **0** | **0,0** | **3** | **2,5** | **3** | **2,3** |
|  VII(a) Hepatoblastoma | 1 | 1,1 | 1 | 0,6 | 1 | 1,2 | 0 | 0,0 | 2 | 1,9 | 2 | 1,8 |
|  VII(b) Carcinoma hepático | 0 | - | 0 | - | 1 | 0,7 | 0 | 0,0 | 0 | 0,0 | 1 | 0,6 |
|  VII(c) Tumor hepático no especificado | 0 | - | 0 | - | 2 | 2,3 | 0 | 0,0 | 1 | 0,6 | 0 | 0,0 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **VIII Tumores malignos del hueso** | **4** | **3,0** | **6** | **2,7** | **6** | **4,6** | **6** | **4,4** | **11** | **6,9** | **10** | **6,6** |
|  VIII(a) Osteosarcomas | 4 | 3,0 | 3 | 1,3 | 5 | 3,9 | 4 | 2,7 | 6 | 3,8 | 4 | 3,0 |
|  VIII(b) Condrosarcomas | 0 | - | 0 | - | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
|  VIII(c) Sarcoma de Ewing | 0 | - | 1 | 0,6 | 1 | 0,7 | 2 | 1,6 | 3 | 1,9 | 5 | 3,0 |
|  VIII(d) Otros tumores malignos específicos de hueso  | 0 | - | 0 | - | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
|  VIII(e) Otro tumores óseos no especificados | 0 | - | 2 | 0,9 | 0 | 0,0 | 0 | 0,0 | 2 | 1,2 | 1 | 0,6 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **IX Sarcoma - tejidos blandos** | **5** | **4,5** | **15** | **7,2** | **13** | **11,2** | **11** | **9,5** | **8** | **5,1** | **14** | **10,0** |
|  IX(a) Rabdomiosarcoma y sarcoma embrionario | 3 | 2,5 | 5 | 2,6 | 7 | 5,9 | 8 | 7,2 | 4 | 2,6 | 7 | 5,4 |
|  IX(b) Fibrosarcoma, neurofibrosarcoma y otras neoplasias fibromatosis | 2 | 2,0 | 4 | 2,0 | 1 | 0,8 | 1 | 0,7 | 2 | 1,2 | 2 | 1,1 |
|  IX(d) Otros sarcomas de tejido blandos especificados | 0 | - |  |  | 3 | 2,7 | 1 | 1,0 | 2 | 1,2 | 3 | 2,2 |
|  IX(e) Otros sarcomas de tejidos blandos no especificados | 0 | - | 3 | 1,3 | 2 | 1,8 | 1 | 0,7 | 0 | 0,0 | 2 | 1,2 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **X Tumores de células germinales, trofoblásticos** | **4** | **3,8** | **8** | **3,4** | **5** | **3,5** | **5** | **3,6** | **8** | **5,6** | **10** | **7,2** |
|  X(a) Tumores de células germinales intracraneales | 2 | 2,3 | 0 | - | 0 | 0,0 | 1 | 0,7 | 0 | 0,0 | 1 | 0,7 |
|  X(b) Tumores de células germinales extracraneales | 0 | - | 1 | 0,4 | 1 | 0,7 | 1 | 1,0 | 2 | 1,9 | 4 | 3,2 |
|  X(c) Tumores malignos gonadales de células germinales | 0 | - | 7 | 3,0 | 4 | 2,8 | 3 | 2,0 | 4 | 2,5 | 5 | 3,4 |
|  X(d) Carcinoma gonadal | 2 | 1,5 | 0 | - | 0 | 0,0 | 0 | 0,0 | 1 | 0,6 | 0 | 0,0 |
|  X(e) Tumores malignos gonadales y otros no especificados | 0 | - | 0 | - | 0 | 0,0 | 0 | 0,0 | 1 | 0,6 | 0 | 0,0 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **XI Carcinomas y otras neoplasias epiteliales** | **5** | **4,8** | **9** | **3,8** | **6** | **4,3** | **5** | **3,7** | **12** | **7,4** | **8** | **5,1** |
|  XI(a) Carcinoma adrenocortical | 0 | - | **0** | **-** | 0 | 0,0 | 1 | 1,0 | 0 | 0,0 | 0 | 0,0 |
|  XI(b) Carcinoma de tiroides | 0 | - | **3** | **1,2** | 3 | 2,1 | 2 | 1,4 | 5 | 3,1 | 2 | 1,6 |
|  XI(c) Carcinoma nasofaríngeo | 0 | - | **1** | **0,5** | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 | 0 | 0,0 |
|  XI(d) Melanoma maligno | 4 | 3,9 | **1** | **0,4** | 0 | 0,0 | 1 | 0,7 | 3 | 1,8 | 3 | 1,8 |
|  XI(f) Otros carcinomas y los no especificados | 1 | 0,9 | **4** | **0,8** | 3 | 2,2 | 1 | 0,7 | 4 | 2,5 | 3 | 1,7 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **XII Otros tumores malignos y los no especificados** | **2** | **2,0** | **4** | **1,9** | **1** | **1,0** | **2** | **1,7** | **3** | **2,8** | **6** | **4,6** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Todos** | 112 | 107,9 | 233 | 133,1 | 164 | 144,3 | 161 | 132,3 | 207 | 157,3 | 198 | 144,9 |
| Tasa media anual por millón niños-año TEE: Tasa estandarizada por edad por millón (método directo, Población Estándar Mundial) |

|  |
| --- |
| **Tabla 3. Cali, Colombia. Tasa de mortalidad media anual de cáncer infantil por millón según categorías diagnósticas, durante 1984-2011.** |
| **Sexo** | **Categorías diagnosticas** | **1984-1988** | **1989-1993** | **1994-1998** | **1999-2003** | **2004-2008** | **2009-2011** |
| ***n*** | **TEE** | ***n*** | **TEE** | **n** | **TEE** | ***n*** | **TEE** | ***n*** | **TEE** | ***n*** | **TEE** |
| **Ambos** | Leucemia | 55 | 26,6 | 73 | 32,8 | 85 | 36 | 85 | 33,1 | 72 | 25,5 | 35 | 19,0 |
|  | Linfoma | 16 | 7,8 | 21 | 9 | 22 | 9,3 | 14 | 5,1 | 6 | 1,9 | 4 | 1,9 |
|  | Neoplasias del SNC | 19 | 8,9 | 16 | 7,3 | 20 | 7,9 | 26 | 10 | 29 | 10 | 27 | 16,1 |
|  | Retinoblastoma | 3 | 1,6 | 7 | 3,5 | 4 | 1,9 | 4 | 1,9 | 1 | 0,5 | 2 | 1,3 |
|  | Tumores renales | 7 | 3,2 | 5 | 2,3 | 6 | 2,2 | 6 | 2,7 | 6 | 2,1 | 2 | 1,1 |
|  | Tumores hepáticos | 7 | 3,6 | 4 | 2 | 2 | 1,1 | 1 | 0,5 | 5 | 2,1 | 1 | 0,8 |
|  | Tumores malignos del hueso | 6 | 2,7 | 4 | 1,6 | 5 | 1,8 | 8 | 2,7 | 7 | 2,1 | 3 | 1,4 |
|  | Sarcoma - tejidos blandos | 4 | 1,9 | 5 | 2,5 | 9 | 4 | 2 | 0,7 | 4 | 1,4 | 1 | 0,5 |
|  | Tumores de células germinales | - | - | 2 | 1 | 2 | 0,8 | 1 | 0,3 | - | - | - | - |
|  | Carcinomas y otras neoplasias malignas | 12 | 6,2 | 12 | 5,5 | 19 | 8,8 | 11 | 4,7 | 12 | 4,9 | 12 | 7,2 |
|  | Otros tumores malignos  | 8 | 3,7 | 12 | 5,5 | 18 | 7,7 | 22 | 9,3 | 12 | 4,6 | 7 | 3,8 |
|  | Todos los tumores malignos | 137 | 66,2 | 161 | 73 | 192 | 81,8 | 180 | 71 | 154 | 55,1 | 94 | 52,9 |
| **Masculino** | Leucemia | 27 | 26 | 34 | 30 | 45 | 38,7 | 52 | 40 | 36 | 24,2 | 15 | 17 |
| Linfoma | 11 | 10,3 | 15 | 13,1 | 14 | 11,1 | 10 | 7 | 3 | 1,8 | 2 | 1,8 |
| Neoplasias del SNC | 12 | 10,9 | 7 | 6,4 | 11 | 8,6 | 11 | 8,8 | 13 | 9,2 | 18 | 21 |
| Retinoblastoma | 2 | 2,1 | 3 | 2,8 | 1 | 1 | 2 | 1,9 | - | - | - | - |
| Tumores renales | 5 | 4,5 | 4 | 3,7 | 2 | 1,5 | 2 | 1,7 | 2 | 1,6 | 1 | 1 |
| Tumores hepáticos | 4 | 4,2 | - | - | 1 | 1,1 | - | - | 2 | 1,8 | 1 | 1,5 |
| Tumores malignos del hueso | 4 | 3,4 | 1 | 0,8 | 4 | 3 | 3 | 2,2 | 4 | 2,5 | - | - |
| Sarcoma - tejidos blandos | 1 | 0,9 | 3 | 2,9 | 3 | 2,8 | 1 | 0,7 | 2 | 1,5 | 1 | 1 |
| Tumores de células germinales | - | - | - | - | - | - | - | - | - | - | - | - |
| Carcinomas y otras neoplasias malignas | 6 | 5,8 | 7 | 6,9 | 8 | 7,6 | 4 | 3,5 | 8 | 6,5 | 6 | 7,3 |
| Otros tumores malignos  | 5 | 4,6 | 7 | 6,6 | 8 | 6,4 | 14 | 11,3 | 5 | 3,8 | 3 | 3,4 |
| Todos los tumores malignos | 77 | 72,8 | 81 | 73 | 97 | 81,7 | 99 | 77,1 | 75 | 52,8 | 47 | 54,1 |
| **Femenino** | Leucemia | 28 | 27,1 | 39 | 35,7 | 40 | 33,3 | 33 | 25,9 | 36 | 26,9 | 20 | 21,0 |
| Linfoma | 5 | 5,3 | 6 | 4,8 | 8 | 7,5 | 4 | 3,2 | 3 | 2 | 2 | 2,0 |
| Neoplasias del SNC | 7 | 6,9 | 9 | 8,2 | 9 | 7,2 | 15 | 11,1 | 16 | 10,9 | 9 | 10,9 |
| Retinoblastoma | 1 | 1,1 | 4 | 4,3 | 3 | 2,9 | 2 | 1,9 | 1 | 0,9 | 2 | 2,6 |
| Tumores renales | 2 | 2 | 1 | 0,9 | 4 | 3 | 4 | 3,8 | 4 | 2,6 | 1 | 1,1 |
| Tumores hepáticos | 3 | 2,9 | 4 | 4 | 1 | 1,1 | 1 | 1 | 3 | 2,5 | - | - |
| Tumores malignos del hueso | 2 | 2,1 | 3 | 2,5 | 1 | 0,7 | 5 | 3,2 | 3 | 1,8 | 3 | 2,8 |
| Sarcoma - tejidos blandos | 3 | 2,9 | 2 | 2,1 | 6 | 5,3 | 1 | 0,6 | 2 | 1,3 | - | - |
| Tumores de células germinales | - | - | 2 | 2,1 | 2 | 1,7 | 1 | 0,6 | - | - | - | - |
| Carcinomas y otras neoplasias malignas | 6 | 6,6 | 5 | 4,1 | 11 | 10,1 | 7 | 6 | 4 | 3,2 | 6 | 7,0 |
| Otros tumores malignos  | 3 | 2,7 | 5 | 4,4 | 10 | 9,2 | 8 | 7,3 | 7 | 5,5 | 4 | 4,2 |
| Todos los tumores malignos | 60 | 59,6 | 80 | 72,9 | 95 | 81,9 | 81 | 64,8 | 79 | 57,5 | 47 | 51,6 |
| Tasa media anual por millón TEE: Tasa estandarizada por edad por millón (método directo, Población Estándar Mundial) |
|  |

|  |
| --- |
| **Tabla 4. Cali, Colombia. Tendencia de las tasas de incidencia y mortalidad por cáncer infantil durante el periodo 1977-2011.** |
| **Neoplasia** | **Sexo** | **Incidencia** |  | **Mortalidad** |
| **Total** |  | **Total** |
| **A.P.C**  | **I.C. 95%** |  | **A.P.C**  | **I.C. 95%** |
| Leucemia | Hombre | 0,6 | -0,5 | 1,7 |   | -0,6 | -2,7 | 1,5 |
|  | Mujer | 1,4\* | 0,5 | 2,4 |  | -1,5 | -3,4 | 0,4 |
|   | Ambos | 1,0\* | 0,2 | 1,8 |   | -1,2 | -2,6 | 0,3 |
| Linfomas  | Hombre | -0,2 | -1,4 | 1,0 |  | ~ | ~ | ~ |
|  | Mujer | ~ | ~ | ~ |  | ~ | ~ | ~ |
|   | Ambos | -0,2 | -1,2 | 0,9 |  | -6,4\* | -9,3 | -3,3 |
| S.N.C  | Hombre | ~ | ~ | ~ |   | ~ | ~ | ~ |
|  | Mujer | 1,5 | -0,2 | 3,2 |  | ~ | ~ | ~ |
|   | Ambos | 1,3\* | 0,3 | 2,4 |   | 1,8 | -0,4 | 4,0 |
| Otros | Hombre | 1,0 | -0,1 | 2,2 |   | -2,0 | -4,1 | 0,2 |
|  | Mujer | 0,6 | -0,5 | 1,8 |  | ~ | ~ | ~ |
|   | Ambos | 0,9\* | 0,0 | 1,7 |   | -1,5\* | -3,0 | -0,1 |
| Total | Hombre | 0,8\* | 0,2 | 1,4 |   | -1,3 | -2,6 | 0,0 |
|  | Mujer | 1,0\* | 0,2 | 1,8 |  | -1,1 | -2,3 | 0,1 |
|   | Ambos | 0,9\* | 0,4 | 1,5 |   | -1,1\* | -2,0 | -0,3 |
| ~ No pudo ser estimado (valor = 0 en tasas anuales)APC: Porcentaje Anual de Cambio (Del inglés Annual Percent Change) \*APC es significativamente diferente de cero (p<0,05) |

|  |
| --- |
| **Figura 1. Cali, Colombia. Supervivencia observada al cáncer infantil con estimaciones a 1, 3 y 5 años y seguimiento hasta junio de 2012.** |
| **05_01_1LeucemiasColor** | **05_01_2LinfomasColor** |
| **05_01_3SNColor** |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|

|  |
| --- |
| **Tabla 5. Cali, Colombia. Supervivencia observada al cáncer infantil con estimaciones a 1, 3 y 5 años y seguimiento hasta junio de 2012.** |
| **Categorías diagnósticas** |  |  | **1992-1996** |  | **1997-2001** |  | **2002-2006** |  | **2007-2011** |
|  |  | **Intervalo (años)** |  | **Intervalo (años)** |  | **Intervalo (años)** |  | **Intervalo (años)** |
| ***n*** |  | **1** | **3** | **5** | ***n*** | **1** | **3** | **5** | ***n*** | **1** | **3** | **5** | ***n*** | **1** | **3** | **5** |
| I Leucemia | 139 | \* | 52,2 | 34,3 | 24,9 | 158 | 65,6 | 42,9 | 37,9 | 150 | 80,1 | 60,0 | 51,8 | 147 | 80,2 | 70,7 | ~ |
|   |   | • | 4,9 | 4,7 | 4,3 |   | 3,9 | 4,1 | 4,0 |   | 3,4 | 4,3 | 4,6 |   | 3,4 | 4,3 | ~ |
| II Linfomas y neoplasias reticuloendoteliales | 46 |  | 76,5 | 62,2 | 57,4 | 50 | 73,4 | 65,8 | 63,1 | 63 | 85,5 | 76,0 | 70,8 | 61 | 90,6 | 90,6 | ~ |
|  |  |  | 8,9 | 10,4 | 10,6 |  | 6,9 | 7,5 | 7,6 |  | 4,8 | 5,8 | 6,5 |  | 4,0 | 4,0 | ~ |
| III SNC intracraneales e intraespinales | 47 |  | 40,7 | 33,3 | 29,6 | 71 | 54,5 | 46,1 | 44,3 | 71 | 69,3 | 52,8 | 38,3 | 72 | 60,3 | 31,1 | **-** |
|   |   |  | 9,2 | 8,9 | 8,6 |   | 6,2 | 6,3 | 6,3 |   | 5,8 | 6,5 | 7,0 |   | 6,5 | 9,7 | **-** |
| IV Tumores del sistema nervioso simpático | 9 |  | 19,4 | 0,0 | 0,0 | 11 | 77,8 | 66,7 | 55,6 | 8 | 58,3 | 58,3 | ~ | 13 | 43,3 | ~ | ~ |
|  |  |  | 17,2 | 0,0 | 0,0 |  | 13,9 | 15,7 | 16,6 |  | 18,6 | 18,6 | ~ |  | 17,9 | ~ | ~ |
| V Retinoblastoma | 11 |  | 30,3 | 30,3 | 30,3 | 21 | 88,2 | 82,4 | 82,4 | 10 | 90,0 | 90,0 | 90,0 | 14 | 91,7 | ~ | ~ |
|   |   |   | 24,9 | 24,9 | 24,9 |   | 7,8 | 9,2 | 9,2 |   | 9,5 | 9,5 | 9,5 |   | 8,0 | ~ | ~ |
| VI Tumores renales | 10 |   | 100,0 | 57,1 | 42,9 | 20 | 92,9 | 78,6 | 78,6 | 17 | 87,8 | 75,3 | 58,1 | 17 | 87,5 | 75,0 | ~ |
|   |   |   | 0,0 | 18,7 | 18,7 |   | 6,9 | 11,0 | 11,0 |   | 8,1 | 10,7 | 13,7 |   | 8,3 | 13,6 | ~ |
| VII Tumores hepáticos | 5 |  | **-** | **-** | **-** | 0 | ~ | ~ | ~ | 6 | 16,7 | 16,7 | 16,7 | 5 | 66,7 | **-** | **-** |
|  |  |  | **-** | **-** | **-** |  | ~ | ~ | ~ |  | 15,2 | 15,2 | 15,2 |  | 27,2 | **-** | **-** |
| VIII Tumores malignos del hueso | 11 |   | 90,9 | 60,6 | 45,5 | 14 | 58,3 | 33,3 | 33,3 | 27 | 86,5 | 52,1 | 45,6 | 17 | 90,9 | 39,8 | **-** |
|   |   |   | 8,7 | 18,4 | 19,1 |   | 14,2 | 13,6 | 13,6 |   | 7,2 | 11,1 | 11,4 |   | 8,7 | 17,5 | **-** |
| IX Sarcomas - tejidos blandos | 25 |  | 61,7 | 41,1 | 41,1 | 23 | 61,9 | 61,9 | 61,9 | 18 | 92,3 | 69,2 | 69,2 | 29 | 90,1 | ~ | ~ |
|  |  |  | 12,5 | 12,8 | 12,8 |  | 11,4 | 11,4 | 11,4 |  | 7,4 | 12,8 | 12,8 |  | 7,0 | ~ | ~ |
| X Células germinales y trofoblásticas | 10 |   | 60,0 | 40,0 | 40,0 | 9 | 77,8 | 55,6 | 55,6 | 12 | 77,1 | 77,1 | 64,3 | 17 | 93,3 | ~ | ~ |
|   |   |   | 21,9 | 21,9 | 21,9 |   | 13,9 | 16,6 | 16,6 |   | 14,4 | 14,4 | 16,8 |   | 6,4 | ~ | ~ |
| XI Carcinomas y otras neoplasias epiteliales | 14 |  | 64,3 | 53,6 | 42,9 | 9 | 75,0 | 60,0 | 60,0 | 20 | 88,7 | 81,8 | 81,8 | 15 | 83,6 | ~ | ~ |
|  |  |  | 14,9 | 15,8 | 15,9 |  | 15,3 | 18,2 | 18,2 |  | 7,6 | 9,6 | 9,6 |  | 10,8 | ~ | ~ |
| XII Otros tumores malignos y los no especificados | 2 |   | **-** | **-** | **-** | 2 | **-** | **-** | **-** | 6 | 50,0 | 50,0 | 50,0 | 9 | 50,0 | ~ | ~ |
|   |   |   | **-** | **-** | **-** |   | **-** | **-** | **-** |   | 20,4 | 20,4 | 20,4 |   | 18,6 | ~ | ~ |
| Total | 329 |   | 55,4 | 38,6 | 31,6 | 388 | 67,0 | 51,5 | 48,3 | 408 | 78,9 | 63,0 | 54,9 | 416 | 79,1 | 64,8 | **-** |
|   |   |   | 3,4 | 3,4 | 3,2 |   | 2,5 | 2,7 | 2,7 |   | 2,1 | 2,6 | 2,8 |   | 2,2 | 3,1 | **-** |
| \* Supervivencia observada (%). • Error estándar | ~ No pudo ser estimado (Valor = 0 en tasas anuales) |

 |
|  |